Psychiatrie supplementum 1/2019 (1)
ODBORNÁ SYMPOZIA ......................................................................................................... 6
Léčba psychofarmaky v rámci probíhající reformy psychiatrické péče (PS ČLS JEP) .......... 6
Ako budeme liečiś duševné poruchy na Slovensku? ............................................................. 6
Riziko rozvoje psychózy v populaci adolescentů: diagnostika, výzkum, intervence .............. 7
Vybrané biologické markery u schizofrenie –
současný pohled a dopad na klinickou praxi .......................................................................... 9
Terapeutické ovlivnění agitovanosti a násilí .......................................................................... 10
Strategie psychofarmakologické léčby při aplikaci stimulačních metod ................................ 12
Neurobiologie OCD: od animálních modelů k novým možnostem
psychofarmakologické léčby ................................................................................................. 13
Hraniční porucha osobnosti .................................................................................................. 14
(Ne)Bezpečná SSRI? ............................................................................................................ 15
Impulzivita u poruch osobnosti .............................................................................................. 17
Mikrobiom a poruchy příjmu potravy ..................................................................................... 19
První neuropsychiatrický pohár: videokazuistický kvíz .......................................................... 20
Psychedelika: problémové děti psychofarmakologie II .......................................................... 20
Psychické poruchy a aldosterón ............................................................................................ 22
Souvislosti mezi vývojem percepčních mechanismů a úrovní kognitivních funkcí ................ 24
Nové krevní biomarkery pro včasnou diagnostiku, prognózu
a průběh Alzheimerovy nemoci ............................................................................................. 26
Systém ochranného léčení v České republice II.
Otázky a otazníky kolem ochranného léčení ........................................................................ 27
Limity ochranného léčení a společnosti ................................................................................ 27
Ochranné léčení ve formě ambulantní vs. ochranné léčení ve formě ústavní ...................... 27
Ochranné léčení – Trendy farmakoterapie ........................................................................... 27
Neurotransmiterové systémy v synchronizaci cirkadiánních hodin ...................................... 28
Edukační dopoledne ČNPS: Léčba psychofarmaky 2018 ................................................... 30
WORKSHOPY ..................................................................................................................... 31
Ctnosti jako zdroje psychopatologie ovlivňující spolupráci při její
farmakoterapii u různých typů pacientů ............................................................................... 31
Léčba duševních poruch v těhotenství a poporodním období ............................................. 31
Zdroje informací z transformovaných dat IVA plus a CPT II a jejich využití v praxi ............. 31
Deset statečných – anankastická porucha osobnosti .......................................................... 31
Transkulturální psychiatrie ................................................................................................... 32
Rapsodie v psychofarmakoterapeutickém kontaktu aneb
Jak se dohodnouts pacientem na užívání léků .................................................................... 32
NOVÝ VÝZKUM ................................................................................................................... 33
Varia1 ................................................................................................................................... 33
Varia 2 .................................................................................................................................. 35
SCIENTIFIC SYMPOSIA ....................................................................................................... 6
Psychopharmacological treatment within the ongoing reform
of psychiatric care in Czech Republic .................................................................................... 6
How are we going to treat mental disorders in Slovakia? ...................................................... 6
Risk of developing psychosis in the population of adolescents:
diagnostics, research, intervention ........................................................................................ 7
Selected biological markers in schizophrenia –
recent aspects and clinical significance ................................................................................. 9
Management of acute agitation and violence ....................................................................... 10
Strategy of psychopharmacological treatment
in application of stimulative methods .................................................................................... 12
Neurobiology of OCD: from animal models to the novel approaches
to psychopharmacological treatment .................................................................................... 13
Borderline personality disorder ............................................................................................. 14
(Un)Safe SSRIs? .................................................................................................................. 15
Impulsivity in patients with personality disorders .................................................................. 17
Microbiom and eatig disorders .............................................................................................. 19
The first neuropsychiatric cup: case study quiz .................................................................... 20
Psychedelics: „problem children“ of psychopharmacology II ................................................ 20
Psychiatric disorders and aldosteron .................................................................................... 22
Relation between the development of perception
and the operation of cognitive processes .............................................................................. 24
Novel blood-based biomarkers for early diagnosis, prognosis
and progress of Alzheimer’s disease .................................................................................... 26
A system of protective treatment in Czech republic part II .................................................... 27
Limits of protective treatment and society ............................................................................. 27
Protective treatment in outpatient and inpatient form ............................................................ 27
Protective treatment – Trends in pharmacotherapy ............................................................... 27
Neurotransmitter systems in synchronization of circadian clocks .......................................... 28
Educational morning CNPS: Treatment of psychopharmaceuticals 2018 .............................. 30
WORKSHOPS ........................................................................................................................ 31
Virtues as a sources of psychopathology influencing cooperation
in its pharmacotherapy in differenttypes of patients ............................................................... 31
Treatment of mental disorders in pregnancy and perinatal period ......................................... 31
Sources of information from the transformed IVA plus
and CPT II data and their use in practice ............................................................................... 31
The magnificent ten – anankastic (obsessive-compulsive) personality disorder .................... 31
Transkultural psychiatry .......................................................................................................... 32
Rapsody in psychopharmacotherapeutical contact
– how to concludewith patient on the drug usage ................................................................... 32
NEW RESEARCH ................................................................................................................... 33
Varia 1 ..................................................................................................................................... 33
Varia 2 ..................................................................................................................................... 35